Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sézary syndrome with variable CD30 expression level: A multi-institution collaborative project Academic Article uri icon

Overview

MeSH Major

  • Antigens, CD30
  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Immunoconjugates
  • Mycosis Fungoides
  • Sezary Syndrome
  • Skin Neoplasms

abstract

  • Brentuximab vedotin demonstrated significant clinical activity in treatment-refractory or advanced MF or SS with a wide range of CD30 expression levels. Additional biomarker studies may help optimize rational design of combination therapies with brentuximab vedotin.

publication date

  • November 10, 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5089160

Digital Object Identifier (DOI)

  • 10.1200/JCO.2014.60.3969

PubMed ID

  • 26195720

Additional Document Info

start page

  • 3750

end page

  • 8

volume

  • 33

number

  • 32